CCMP Confirms Buy of Medpace, Deal Valued at Roughly $500 Mln

CCMP Capital Advisors is buying 80% of Medpace via a recap. Management will own the rest, according to a statement Monday. News of the deal was reported by peHUB last week. The transaction is valued at roughly $500 million, a person said. Cincinnati-based Medpace is a CRO that provides Phase I-IV core development services for drug, biologic, and device programs.


Medpace, Inc. a full-service global clinical research organization today announced a plan to complete an equity recapitalization with affiliates of  CCMP Capital Advisors, LLC.    This relationship will allow Medpace to add global operational depth and continue their reputation as a company well known for therapeutic and operational excellence in conducting Phase I-IV clinical studies.

“Our relationship with CCMP will bring many benefits to our customers, employees, and shareholders,” said August Troendle, President and CEO, Medpace.  “The transaction will provide resources to make the strategic long-term investments that are needed to advance our leadership position, grow the core business, and expand our global reach.”

Medpace expects to finalize the deal in June 2011.  Following the closing, CCMP will own 80% of the company and the current Medpace management team will own a 20% equity share.  August J. Troendle will remain as the President and CEO and the current management team will remain in place.  Medpace will continue to be headquartered in Cincinnati, OH.



Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at


CCMP Capital Advisors, LLC specializes in upper-middle market buyouts and growth equity investments of $100 million to $500 million in the U.S. and Europe.  CCMP focuses on generating alpha through the operational transformation of its portfolio companies.  With offices in New York, Houston and London, CCMP invests in four primary industries: Consumer, Industrial, Energy and Healthcare.  Selected investments under management include: ARAMARK Corporation, Chaparral Energy, Edwards Group, Francesca’s Collections, Generac Power Systems, Infogroup, Jetro Holdings, LHP Hospital Group and Warner Chilcott.